Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ pain related to treatment ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 3
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ hyperpigmentation ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 5
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ depigmentation ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 1 [0.07, 15.12]
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ purpura ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 15
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ total ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 4.67 [1.53, 14.26]
Studies not reported
Very low
Regression of PSR: change in number and size (in clock hours or in degrees of retinal circumference) of new blood vessels · children and adults with SCD and PSR
1 finding from 1 review
Development of new PSR: proliferation of blood vessels at a new area/progression of existing PSR after treatment · children and adults with SCD and PSR
1 finding from 1 review
Quality of life · children and adults with SCD and PSR
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in visual loss associated with PSR: visual loss is defined by the deterioration of visual acuity of 3 lines or more with the Snellen chart · children and adults with SCD and PSR
1 finding from 1 review
Occurence of vitreous haemorrhage · children and adults with SCD and PSR
1 finding from 1 review
Adverse effects · children and adults with SCD and PSR
1 finding from 1 review
Overall improvement in CTS: SSS: short term (< 3 months) Scale from: 1 to 5 · carpal tunnel syndrome
1 finding from 1 review
Overall improvement in CTS: SSS: long term ‐ not measured · carpal tunnel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall improvement in CTS: FSS: short term (< 3 months) Scale from: 1 to 5 · carpal tunnel syndrome
1 finding from 1 review
Overall improvement in CTS: FSS: long term ‐ not reported · carpal tunnel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · carpal tunnel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall improvement in CTS: SSS: short term (< 3 months) Scale from: 1 to 5 · carpal tunnel syndrome
1 finding from 1 review
Overall improvement in CTS: SSS: long term ‐ not measured · carpal tunnel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall improvement in CTS: FSS: short term (< 3 months) Scale from: 1 to 5 · carpal tunnel syndrome
1 finding from 1 review
Overall improvement in CTS: FSS: long term ‐ not reported · carpal tunnel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found